News Briefs: Optum to Include Humira Biosimilars in Formulary

UnitedHealth Group’s Optum Rx PBM said that it will incorporate as many as three new biosimilars in its formulary to compete with AbbVie Inc.’s Humira, the immunosuppressant biologic that consistently is the most costly drug to the U.S. health care system. However, Optum will still cover Humira: it will be placed on the same tier as the new biosimilars. According to Optum, the company spends at least $20 billion on Humira every year, according to Bloomberg.

Merck & Co. Inc. will acquire Imago BioSciences Inc. for $1.35 billion, the companies said on Monday. Imago’s lead product is “bomedemstat (IMG-7289), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor, is currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia (ET), myelofibrosis (MF), and polycythemia vera (PV), in addition to other indications,” according to a Merck press release. The purchase could shore up Merck’s portfolio of treatments for blood and bone marrow cancers. At present, Bristol-Meyers Squibb Co. and a joint venture of Incyte Corp. and Novartis AG lead the market in those categories.

© 2023 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

bills-and-pills
January 26

Medicare Enrollees May Still Face Affordability Issues After Part D Benefit Redesign

READ MORE
pills-in-hand
January 26

ICER Report Aims to Nudge Payers Toward Fairer Drug Coverage Policies

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
January 26

News Briefs: Lilly Alzheimer’s Drug Fails to Win Accelerated Approval

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today